Morgan Stanley analyst Thibault Boutherin initiated coverage of Novartis (NVS) with an Underweight rating and CHF 91 price target The company has a solid outlook but limited earnings upside aside from loss of exclusivity pushback and tail products, the analyst tells investors in a research note. The firm sees a lack of catalysts for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis agrees to acquire Anthos for up to $3.1B
- Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
- Trump Trade: President advocates to close carried interest tax loophole
- White House readying order to fire thousands of federal health workers, WSJ says